Physician profile
Blake W Dowell
NPI 1407089147
$1,986.38
in general payments reported to CMS, 2019-2025
15 companies · $465 in 2025
The $465 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $147 · 2021: $144 · 2022: $378 · 2023: $259 · 2024: $355 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $649.30 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $387.35 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Shire North American Group INC | $144.90 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $137.20 | 2019-2025 | Acuvue |
| Abbvie INC. | $133.69 | 2022 | |
| Sun Pharmaceutical Industries INC. | $118.71 | 2025 | |
| Harrow Eye, LLC | $108.60 | 2024 | Vevye |
| Synergeyes, INC. | $64.63 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $55.73 | 2024 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $47.15 | 2020-2023 | |
| Allergan, INC. | $42.01 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $29.14 | 2022-2024 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.64 | 2021 | |
| Thea Pharma INC. | $21.14 | 2022 | |
| Horizon Therapeutics Plc | $20.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Dowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.